The most commonly reported side effects of diphemanil include nausea, hyperkalaemia, and urinary tract infection, based on 16 FDA adverse event reports from 2007 to 2022. 12.5% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for diphemanil.
These are voluntary reports and do not establish that diphemanil caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside diphemanil. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
56.3% of diphemanil adverse event reports involve female patients and 43.8% involve male patients. The largest age group is elderly at 62%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking diphemanil when the adverse event was reported.
Diphemanil is sold under the brand name Prantal.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.